3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Endocrine
2
NET
1
Genitourinary
1
Conditions
Neuroendocrine Tumors
1
Neuroendocrine Prostate Cancer
1
Neoplasms
1
Interventions
Everolimus
25
Magnetic Resonance Spectroscopy
13
pembrolizumab
12
pasireotide
12
Sunitinib
11
Octreotide
11
lanreotide
10
cabozantinib
10
lenvatinib
8
Sorafenib
8
Cisplatin
8
Temozolomide
7
Etoposide
7
Bevacizumab
7
pazopanib
6
Paclitaxel
6
Nivolumab
6
Doxorubicin
6
Carboplatin
6
Capecitabine
6
vandetanib
5
gallium Ga 68 dotatate
5
Specimen Handling
5
trametinib
4
lutetium Lu 177 dotatate
4
dabrafenib
4
Mitotane
4
Iodine-131
4
telotristat ethyl
3
surufatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
AMG 757
×
Endocrine
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts
NCT04702737
2025-09-12
DeLLpro-300
Amgen
Phase 1
Completed
41 enrolled
19 charts